Related Experiment Video

Updated: Mar 21, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.5K

A natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancer

Do Young Lim1, Seung Ho Shin1,2, Mee-Hyun Lee1,3

  • 1The Hormel Institute, University of Minnesota, MN, USA.

Oncotarget
|May 12, 2016
PubMed

Insights

Catechol, a natural compound, effectively targets the ERK2/c-Myc pathway, inhibiting lung cancer growth in preclinical models. This molecule shows promise as a novel therapeutic agent for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal Growth Factor Receptor (EGFR)/RAS/Mitogen-Activated Protein Kinase (MAPK) signaling is crucial in lung cancer development.
  • Constitutive activation of extracellular signal-regulated kinase 2 (ERK2) is prevalent in lung cancer patients, presenting a therapeutic target.

Purpose of the Study:

  • To investigate the therapeutic potential of catechol against lung cancer.
  • To elucidate the mechanism of action of catechol in targeting the ERK2 signaling pathway.

Main Methods:

  • In vitro kinase assays and X-ray crystallography to confirm catechol's binding to ERK2.
  • Cell-based assays to assess catechol's effects on cancer cell growth, cell cycle, and protein expression (e.g., c-Myc).
  • In vivo studies using allograft, xenograft, and patient-derived xenograft (PDX) models to evaluate tumor growth inhibition.

Main Results:

  • Catechol suppressed lung cancer cell growth in a dose-dependent manner and inhibited ERK2 kinase activity.
  • Direct binding of catechol to the ERK2 active site was confirmed via X-ray crystallography.
  • Catechol treatment led to decreased phosphorylation and down-regulation of c-Myc, induced G1 phase arrest, and inhibited tumor growth in vivo.

Conclusions:

  • Catechol effectively inhibits the ERK2/c-Myc signaling axis, reducing lung cancer progression.
  • Catechol demonstrates significant therapeutic potential as a natural small molecule agent for lung cancer treatment.
  • These preclinical findings support the future clinical investigation of catechol for lung carcinogenesis.
Keywords:
ERK2c-Myccatechollung cancernatural compound

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

900
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K